We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sareum Holdings Plc | LSE:SAR | London | Ordinary Share | GB00BMC3RJ87 | ORD GBP 0.0125 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.50 | 13.73% | 29.00 | 28.00 | 30.00 | 29.50 | 25.50 | 25.50 | 924,968 | 16:28:45 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -3.19M | -0.0469 | -6.18 | 19.74M |
From May 2022 to May 2024
By Michael Susin
Sareum Holdings PLC said on Monday that GSK PLC has completes the acquisition of Sierra Oncology for US$1.9 billion in cash and therefore will own Sareum's cancer treatment SRA737 license.
The U.K. drug-development company said that Sareum is eligible to receive a 27.5% share of any future milestone payments, and royalties on future sales under an amended $299 million licensing deal between Sierra and CRT Pioneer Fund LP in 2020.
The SRA737 is an oral treatment currently in clinical stage which targets cancer-cell replication and DNA-damage repair mechanisms.
"The dosing of the first patient with SRA737 in any new clinical trial would result in a $2.0 million payment from Sierra (now GSK), with 27.5% of this due to Sareum," it added.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
July 04, 2022 02:39 ET (06:39 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Sareum Chart |
1 Month Sareum Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
